The mother cannabinoid — the precursor the plant converts into THC, CBD, and CBC. What follows is the verified pharmacology and the (small) human record, graded and hedged.
In the plant, cannabigerolic acid (CBGa) is the single precursor three synthases branch into the THC, CBD, and CBC lines. That is the literal basis for calling CBG the “mother cannabinoid.” CBG itself is non-intoxicating.
These are in-vitro findings — how the molecule behaves in controlled lab assays, not a description of human clinical effects.
In lab studies, CBG interacts with several of the body's signalling systems — including adrenaline and serotonin receptors, the cannabinoid CB1 receptor, and temperature-sensing channels. What this means for people is still largely unknown; switch to Researcher depth for the receptor-level detail and binding values.
In vitro, CBG binds the α2-adrenoceptor as a potent agonist. Because α2 agonism can lower blood pressure, this is the source of the platform's cardiovascular caution. Validated in vitro — receptor pharmacology, not a human clinical grade; whether this changes blood pressure in people is uncharacterized (Hypothesized).
In vitro, CBG acts as a 5-HT1A antagonist — the opposite direction to CBD, a useful and verified contrast when reasoning about serotonergic effects. Validated in vitro — receptor pharmacology, not a human clinical grade.
In vitro, CBG behaves as a CB1 antagonist; it is non-intoxicating. Validated in vitro — receptor pharmacology, not a human clinical grade.
In vitro, CBG activates and then desensitises TRPV1/TRPV2 channels. Validated in vitro — receptor pharmacology, not a human clinical grade.
In vitro, CBG antagonises the TRPM8 cold/menthol channel. Validated in vitro — receptor pharmacology, not a human clinical grade.
One acute human trial of effects and a preclinical anti-inflammatory signal. Graded honestly.
In the only human trial of CBG's effects on anxiety and stress, a single 20 mg oral dose was associated with lower self-reported anxiety and stress, with no intoxication or impairment (n=34, acute, crossover). One small acute study — Low confidence; not a treatment claim. Other human CBG research exists but measures pharmacokinetics, not effects. Animal studies do not consistently reproduce an anxiety-reducing effect — one found no effect and another reported an anxiety-increasing effect — so the preclinical picture is mixed and does not confirm a benefit.
In a murine (mouse) colitis model, CBG reduced markers of intestinal inflammation. Preclinical only — not evidence of a human effect.
CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
CBG is prohibited by the World Anti-Doping Agency — CBD is the only exempt cannabinoid. In a randomised trial of a broad-spectrum CBD product containing only trace CBG, CBG was detectable in urine after repeated daily use, and concentrations appeared higher after exercise. This is regulatory and testing status, not a health claim. Check the current WADA Prohibited List and your product's COA. (Gillham et al., PMID 40920736.)
Cited as an attributed regulatory and testing note. This paper is in intake review and is not yet a graded entry in the CBG Atlas registry, so it carries no evidence grade here.
A six-rung ladder, high to low. The grade governs the verbs a claim is allowed to use — color never inflates weak evidence.
Settled science — replicated human data, or biochemistry that is not in dispute.
Shown reproducibly in controlled experiments — typically laboratory (in-vitro) work.
An early signal — preclinical (animal) work, or human evidence too limited to settle the question.
Limited and low-confidence — sparse, indirect, or single-source data.
Proposed and plausible — but not yet shown.
Tested, and the evidence does NOT support it. This is a finding against the claim — not an absence of evidence.
Each answer below carries its own evidence grade and hedge — the exact text quoted by answer engines that cite this page.
No. CBG (cannabigerol) is non-intoxicating. In laboratory (in vitro) assays it behaves as an antagonist at the CB1 cannabinoid receptor rather than an activator (Cascio et al., 2010, PMID 20002104). That finding is validated in vitro — receptor pharmacology, not a human clinical evidence grade. It describes how the molecule behaves in controlled lab assays, not a measured clinical effect in people.
Because of where it sits in the plant's biosynthesis, not because of any therapeutic property. Its acidic form, cannabigerolic acid (CBGa), is the single precursor that three synthase enzymes branch into the THC, CBD, and CBC lines. That biosynthetic position is the literal basis for the name.
In laboratory (in vitro) tests and in a mouse infection model, CBG showed activity against methicillin-resistant Staphylococcus aureus (MRSA), including effects on the bacterial membrane and biofilms (Appendino et al., 2008, PMID 18681481; Farha et al., 2020, PMID 32017534). These are preclinical findings only — not tested in humans, and not evidence of benefit as an anti-infective. Evidence grade: Low.
Very little on effects, and we say so plainly. Only one human trial of CBG's effects on anxiety and stress has been published: a double-blind, placebo-controlled crossover study in which a single 20 mg oral dose was given to 34 healthy adults (Cuttler et al., 2024, PMID 39003387). Evidence grade: Low — one small acute study, and not a treatment claim. Other human CBG research is published that is not a graded entry in this registry, and it is NOT confined to pharmacokinetics — it includes work measuring effects, among them a repeated-dose trial whose primary endpoint was null. This answer deliberately does not enumerate it: a hand-kept list of everything outside the registry goes stale as soon as the literature moves, and this one had. The off-registry human record is maintained with its disclosures on our safety page.
The evidence does not support saying so. In the only human trial of CBG's effects on anxiety and stress, a one-time 20 mg oral dose was associated with lower self-reported anxiety and stress in healthy adults, with no intoxication or measurable impairment (Cuttler et al., 2024, PMID 39003387). Animal studies do not consistently reproduce that effect — one found no effect and another reported an anxiety-increasing effect — so the preclinical picture is mixed and does not confirm a benefit. Evidence grade: Low. This is an early signal, not evidence of clinical efficacy.
This is the platform's standing safety caution. In vitro, CBG is a potent agonist at the α2-adrenoceptor (Cascio et al., 2010, PMID 20002104), and α2 agonism can lower blood pressure. Whether that produces a measurable change in people, and of what magnitude, is uncharacterized — evidence grade: Hypothesized. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
The consumer question corpus for CBG, kept on the monograph rather than split to a separate route. Identity, chemistry and non-intoxication are stated as fact with a grade; every effect claim travels with the grade the gated claims registry gives it, and where we hold nothing we say so instead of guessing.
40 questions are answered here. 36 carry a verified grade on the six-rung evidence ladder. 4 are marked with an evidence state rather than a rung — most often no primary evidence, which means our registry holds nothing on that question. That is not the same claim as not supported, and we do not render it as one.
CBG (cannabigerol) is a non-intoxicating cannabinoid found naturally in hemp and cannabis. It's often called the "mother cannabinoid" because its acid form, CBGA, is the precursor the plant uses to build THC, CBD, and CBC. Its chemistry is well characterized; the human evidence is still early.
CBG stands for cannabigerol — a phytocannabinoid with the chemical formula C₂₁H₃₂O₂. "Cannabi-" points to its cannabis origin and "-gerol" to its geranyl-derived structure. It is the neutral, decarboxylated form of cannabigerolic acid (CBGA). It is one of the plant's foundational cannabinoids and the starting point for the others.
CBG comes from cannabis and hemp, where the plant first makes cannabigerolic acid (CBGA). Enzymes convert CBGA into the acids that become THC, CBD, and CBC; heat converts leftover CBGA into CBG. Because CBGA is that shared starting point, CBG earns the "mother cannabinoid" name.
CBG is a naturally occurring cannabinoid present in hemp and cannabis, usually at low levels. Most commercial CBG is extracted from CBG-rich hemp or produced by gently heating CBGA (its natural acid form). It is not a synthetic or lab-designed cannabinoid, though some producers now make it via fermentation.
No. CBG does not get you high. In laboratory studies CBG acts as a CB₁ receptor antagonist (Cascio 2010, PMID 20002104) — essentially the opposite of THC, which causes intoxication by activating CB₁. The one human trial in our registry (Cuttler 2024) reported no intoxication and no impairment. Non-intoxicating is Established for CBG.
CBG is non-intoxicating — it does not produce the "high" or impairment THC does, because in vitro it blocks rather than activates the CB₁ receptor (Cascio 2010, PMID 20002104). In the strict sense any compound that affects mood could be called "psychoactive," and one small human trial reported reduced anxiety, graded Low. Non-intoxicating is Established; a mood effect is not.
CBG has no established subjective effect profile. Some users report a subtle sense of calm or focus without a high, but these are anecdotal. The one trial in our registry that measured CBG's effects on anxiety and stress found a single 20 mg dose reduced both, with no intoxication — an early signal graded Low, not a defined "feel." (not medical advice)
There's no established answer for CBG. It is marketed both as a daytime "focus" cannabinoid and as calming, but neither is proven. The one human trial in our registry (Cuttler 2024) reported reduced anxiety and stress after 20 mg, pointing loosely toward "calming" — but it was small, acute and self-reported, and the finding is graded Low. (not medical advice)
As of 2026, hemp-derived CBG is generally federally legal in the US under the 2018 Farm Bill (≤0.3% delta-9 THC); state laws vary. Elsewhere it differs sharply — the EU classifies CBG as an unauthorized novel food, and Canada regulates it as cannabis. General information, not legal advice; verify locally.
As of 2026, hemp-derived CBG is generally federally legal in the US under the 2018 Farm Bill when the product contains ≤0.3% delta-9 THC by dry weight. However, the FDA has not authorized CBG as a dietary supplement or food, and state laws vary. Not legal advice; verify locally.
Not necessarily. Hemp-derived CBG (≤0.3% delta-9 THC) is federally legal under the 2018 Farm Bill, but individual states set their own rules, and some restrict hemp cannabinoids or specific product types. Where you live and the product class both matter. This is general information, not legal advice — verify your state's current law.
CBG's legality varies by country. In the EU, CBG is a novel food and is not authorized for sale as a food or supplement. Canada regulates all phytocannabinoids, including CBG, under the Cannabis Act. In the UK, CBG isn't a controlled drug but falls under the FSA novel-food regime. Not legal advice; verify locally.
No benefit of CBG is established in humans. CBG is marketed for calm, focus, gut comfort and skin, and preliminary animal and laboratory studies report anti-inflammatory and antibacterial activity — preclinical signals graded Emerging, not proven benefits. The one trial in our registry that measured CBG's effects on anxiety and stress (Cuttler 2024) linked a 20 mg dose to lower acute anxiety and stress. Promising, and still unproven. (not medical advice)
CBG is sold in wellness products and marketed for everyday calm, focus, digestive comfort, and skincare, and some users take it that way. These are consumer and marketing uses, not clinically established medical uses. The only human evidence is a single small trial on acute anxiety and stress. (not medical advice)
None of the three is established in humans. For anxiety, one small trial (Cuttler 2024) reported reduced acute anxiety and stress at 20 mg — but a mouse study (Zhou 2022) found no effect on fear memory, so the picture is mixed and graded Emerging at best. Inflammation evidence for CBG is animal-only (Borrelli 2013), and focus is essentially unstudied. Proponents claim more than the science shows. (not medical advice)
Barely. As of 2026 our registry catalogues one controlled human trial of CBG's effects: Cuttler 2024, in which a single 20 mg oral dose reduced self-reported anxiety and stress in 34 adults, with no intoxication or impairment. It was small, acute and self-reported, and the finding is graded Low. Reviews note that human research on CBG is very limited. (not medical advice)
CBG's safety isn't fully established, and the evidence behind that is graded Low. The only controlled human data our registry holds is one acute trial (20 mg, no impairment); long-term use, repeated or higher doses, and drug interactions aren't well studied. Because CBG acts on α₂-adrenoceptors that help regulate blood pressure (Cascio 2010), consult a clinician if you take cardiovascular medication. (not medical advice)
CBG's side-effect profile isn't well characterized. The one human trial in our registry (Cuttler 2024) reported no intoxication or impairment at 20 mg. Anecdotally, users mention dry mouth, drowsiness, or mild digestive upset, as with other cannabinoids, but these aren't confirmed for CBG. Its α₂ activity may affect blood pressure — caution with cardiovascular medication. (not medical advice)
There's no established CBG dose or toxicity threshold, so "too much" isn't defined. The trial in our registry that measured CBG's effects on anxiety and stress studied a single 20 mg dose; higher amounts, repeated use, and overdose risk are unstudied. Because CBG acts on α₂-adrenoceptors linked to blood pressure, over-use is a particular caution on cardiovascular medication. (not medical advice)
Possibly, but specific data is limited. Laboratory studies show CBG acts on α₂-adrenoceptors (Cascio 2010), part of the system regulating blood pressure — so anyone on cardiovascular medication should be cautious and consult a clinician. More broadly, cannabinoids can affect drug-metabolizing enzymes; CBG-specific interaction data isn't established. Ask a pharmacist. (not medical advice)
Standard drug tests screen for THC and its metabolite, not CBG, so pure CBG isn't the target and generally shouldn't register. The real risk is that full-spectrum CBG products can contain trace THC (up to 0.3%), which can accumulate. CBG-specific cross-reactivity data is limited, so caution is wise.
CBG (cannabigerol) is a distinct molecule and is not THC — chemically it's C₂₁H₃₂O₂ and non-intoxicating. However, CBG products can contain THC depending on type: full-spectrum hemp products include trace THC (≤0.3%), while broad-spectrum and isolate products are formulated to remove it. Check the certificate of analysis.
CBG itself isn't what standard tests detect, so it shouldn't cause a failure on its own. But full-spectrum CBG products contain trace THC that can build up with regular use and trigger a positive. Isolate or broad-spectrum products carry less of that risk. CBG-specific cross-reactivity data is limited — graded Low — and no product can be guaranteed test-safe.
CBG comes in several forms. Oils and tinctures are held under the tongue, then swallowed; capsules, softgels, gummies, and beverages are swallowed; topicals are applied to skin; and CBG can be inhaled via vaporized flower or concentrate. Route affects how quickly it's felt. There is no established CBG dose. (not medical advice)
CBG is sold as oils and tinctures, capsules and softgels, gummies and edibles, beverages, topicals and balms, vape products, and hemp flower. Many are blends (often CBG with CBD) rather than CBG alone, and come as full-spectrum, broad-spectrum, or isolate. A third-party certificate of analysis confirms what's actually inside.
There is no established CBG dose. The trial in our registry used a single 20 mg oral dose — that is what was studied, not a recommendation. No official dosing guidelines exist, and safe amounts for repeated or long-term use aren't defined. Consult a clinician, especially if on cardiovascular medication. (not medical advice)
CBG's onset and duration aren't well characterized — reviews note little pharmacokinetic research, and we won't publish numbers we can't verify. In general terms, inhaled and under-the-tongue routes tend to act sooner, while swallowed forms act more slowly but may last longer. CBG-specific timing is not established. (not medical advice)
Both are non-intoxicating, but they're distinct molecules with different targets. In lab studies CBG acts on α₂-adrenoceptors and blocks 5-HT₁ₐ serotonin receptors (Cascio 2010), while CBD activates 5-HT₁ₐ — an opposite direction. CBD is far more studied and has an approved prescription epilepsy medicine; CBG's human evidence in our registry is one small trial.
THC is intoxicating; CBG is not. THC activates the CB₁ receptor as a partial agonist, which produces the "high" and impairment. CBG does the opposite in lab studies, acting as a CB₁ antagonist, and the human trial in our registry found no intoxication. They also differ chemically and in legal status.
CBG and CBN form differently. CBG is the neutral form of CBGA, the plant's biosynthetic starting point, and is non-intoxicating. CBN is the oxidative breakdown product of THC — it builds up as cannabis ages. CBN is widely marketed for sleep, though that isn't established in controlled human studies; CBG is not a sleep product.
There's no honest answer yet for CBG versus CBD. No head-to-head human trials compare them for inflammation, focus, or anything else, so ranking them would go beyond the evidence. Both show only preclinical signals for inflammation and essentially none for focus. We mark this comparison "catalogue in progress." (not medical advice)
CBG's molecular formula is C₂₁H₃₂O₂, giving a molecular weight of about 316.5 g/mol (CAS 25654-31-3). Structurally it's a resorcinol core with a geranyl chain and a five-carbon (pentyl) side chain. It's the neutral, decarboxylated form of cannabigerolic acid (CBGA), C₂₂H₃₂O₄.
CBG is usually extracted from hemp using CO₂ or ethanol, then purified. Yields are low because, in the living plant, most cannabigerolic acid (CBGA) is enzymatically converted into the acids that become THC, CBD, and CBC — leaving little CBG behind. Growers use CBG-rich chemotypes or early harvests to capture more.
Indirectly — CBG's acid form is what does the work. The plant makes cannabigerolic acid (CBGA), then enzymes convert CBGA into THCA, CBDA, and CBCA, which lose CO₂ with heat to become THC, CBD, and CBC. CBG is the neutral form of that same parent acid — hence "mother cannabinoid."
Yes. CBG comes from an acid: cannabigerolic acid (CBGA, C₂₂H₃₂O₄), the raw-plant form. Heating CBGA — decarboxylation, roughly 110–130 °C — removes a carboxyl group as CO₂ and converts it to neutral CBG. CBGA is also the branch point from which THCA, CBDA, and CBCA are made.
CBG is sold online and in some hemp, CBD, and wellness shops as oils, capsules, gummies, and topicals, where hemp-derived products are legal. Availability and legality depend on your jurisdiction and product class. Whatever the source, choose brands that publish a batch-specific third-party certificate of analysis (COA). Not legal advice.
Mostly because it's rare in the plant. In most hemp, cannabigerolic acid (CBGA) is converted into other cannabinoids as the plant matures, leaving very little CBG at harvest. Producing meaningful amounts takes CBG-rich chemotypes, early harvesting, or more biomass and processing — all of which raise the cost versus abundant CBD.
Look for a third-party certificate of analysis (COA) — a lab report, ideally batch-specific and recent. It should confirm the CBG content matches the label, verify THC is within legal limits, and show screening for pesticides, solvents, heavy metals, and microbials. If a seller can't provide one, treat the claims skeptically.
That depends on your goals, and the honest answer is that CBG's science is early. Beyond one small human trial on acute anxiety and stress — a finding graded Low — CBG's benefits are preclinical and unproven. If you try it, choose COA-verified products and, if you take cardiovascular medication, mind the blood-pressure caution. (not medical advice)
Look for a recent, batch-specific third-party COA confirming CBG content and contaminant screening (pesticides, solvents, heavy metals, microbials). Check the spectrum — full-spectrum contains trace THC, broad-spectrum and isolate don't — and that the label matches the COA. Favor transparent brands, and note the α₂ blood-pressure caution if on cardiovascular medication.
Seven compounds, each with its own monograph. The line under each one is what the verified registry actually holds for it — including where that is nothing yet.
The acid CBG comes from, and the shared substrate the three branch synthases compete for. Decarboxylates to CBG with heat.
The propyl (varin) analogue of CBG — a three-carbon side chain instead of five.
Non-intoxicating, and one of the three branch products off the shared CBGA substrate.
Forms as THC ages and oxidises, so it accumulates in stored material rather than being made by the plant directly.
The propyl analogue of CBD, and the varin with the largest published human trial record.
The propyl analogue of THC, with receptor behaviour that differs from it in laboratory work.